Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10796873 | PMC |
| http://dx.doi.org/10.1007/s40744-023-00616-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corrigendum to Dosage Adjustments in Patients With Psoriasis on Etanercept: A Retrospective Chart Review.
J Psoriasis Psoriatic Arthritis
October 2023
[This corrects the article DOI: 10.1177/2475530320910466.].
View Article and Find Full Text PDFMultimodal Imaging of Structural Damage and Inflammation in Psoriatic Arthritis: A comparison of DMARD-Naive and DMARD-Failure Patients.
Rheumatology (Oxford)
August 2024
Department of Radiology and Nuclear Medicine, UMC Utrecht, Utrecht University, Utrecht, the Netherlands.
Objectives: To compare inflammatory and structural differences in active Psoriatic Arthritis (PsA) between disease-modifying antirheumatic drug (DMARD)-naive and DMARD-failure patients using diverse imaging approaches for future analyses. Additionally, to explore the influence of patient characteristics (clinical and demographic variables) on imaging findings.
Methods: Of the 80 patients included from the first cohort of the ongoing multicentre TOFA-PREDICT trial, 40 were DMARD-naive and 40 were DMARD-failure (csDMARD failure; 1 prior bDMARD excluding etanercept was allowed), all meeting classification criteria for PsA with a minimum disease duration of eight weeks.
Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index: a cohort study in a Swiss registry.
BMJ Open
February 2024
Pharmacoepidemiology Group, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland
Article Synopsis
- The study aimed to evaluate the effectiveness of three rheumatoid arthritis treatments (etanercept, infliximab, and abatacept) against adalimumab, focusing on patients with obesity and also considering those who are overweight or normal weight.
- Using data from a Swiss registry, the research followed 2,515 adult RA patients over one year, analyzing their treatment responses based on body mass index (BMI).
- The results showed no significant differences in treatment outcomes, measured by remission rates, among the different therapies across all BMI categories.
Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry.
Ophthalmol Ther
March 2024
Department of Medicine, Surgery and Neurosciences, Ophthalmology Unit, ERN RITA Center, Policlinico "Le Scotte", University of Siena, Viale Bracci 16, 53100, Siena, Italy.
Article Synopsis
- Many biological drug patents have expired, leading to the development of biosimilar agents (BIOs), but their use in children raises concerns, prompting a study on their efficacy and safety for treating pediatric non-infectious uveitis (NIU).
- Data collected from pediatric patients treated with TNF inhibitors BIOs showed a significant decrease in flare-ups and ocular complications, as well as a reduction in the need for glucocorticoids during treatment.
- The study included 47 patients, demonstrating strong treatment retention rates and maintaining visual acuity throughout the therapy, while only recording a few minor adverse events.
Correction: Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA).
Rheumatol Ther
February 2024
Pfizer Pharma GmbH, Berlin, Germany.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!